Second Sight Medical Products Inc (NASDAQ:EYES), the developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, today announced positive five-year outcomes associated with patients using the Argus® II Retinal Prosthesis System (“Argus II”). The Argus II captures images on an eyeglass-mounted miniature video camera, converts the images to electrical pulses, and then transmits those pulses wirelessly to electrodes implanted on the retinal surface, bypassing defunct retinal cells and stimulating the viable retinal cells in patients with severe to profound retinitis pigmentosa (RP).

The paper entitled “Five year safety and performance results from the Argus II Retinal Prosthesis System Clinical Trial” follows the assessment of 30 subjects in the clinical trial (NCT00407602) implanted with the Argus II in 10 centers throughout the United States and Europe.[1] All patients were blind (i.e., with bare light perception or worse) from RP or similar disorders. Throughout five years of clinical study, results showed that patients’ visual function improved after implantation with the Argus II and these improvements were sustained over five years. Patients reported that using Argus II had a positive impact on their wellbeing, including a renewed connection with loved ones and the world around them. Results also demonstrated that the Argus II had an acceptable safety profile.

“For patients with RP who are living in darkness, the long-term benefits of the Argus II in restoring some useful vision represents a very meaningful milestone,” said Lyndon da Cruz, MD, PhD, Consultant Retinal Surgeon at Moorfields Eye Hospital NHS Foundation Trust and lead author for the study. “Perhaps most exciting is the proven ability of the Argus II to increase patients’ functional vision. With the Argus II, patients can perform tasks that would not be possible without the device. This can be a life-altering change. It is good that we have now shown that these changes last for many years after implantation.”

Dr Eman Al Kahtani, MD, Retinal Surgeon and Associate Executive Medical Director of Education, King Khaled Eye Specialist Hospital, Riyadh, said: “At King Khaled Eye Specialist Hospital, we are at the forefront of innovation in ophthalmology and have treated several patients with the Argus II Retinal Prosthesis System, and we see the benefits that patients get from using it in their day to day life. This publication confirms that blind patients can continue to enjoy the benefit of artificial vision five to nine years after surgery, and it increases our confidence and our determination to offer this treatment as an option to alleviate blindness in Saudi Arabia.”

“We are excited to see that the substantial visual improvement gained from the Argus II endures over five years – promising news for patients blinded by RP, as well as for our company’s continued efforts to restore vision,” said Will McGuire, President and CEO of Second Sight. “The study supports the long-term safety profile and benefit of the Argus II system, and these results will continue to drive our approach in the future, both in the development process and in seeking additional regulatory and reimbursement approvals for the Argus II.”

In the Argus II study, three types of visual function tests were performed using computer-run assessments: square localization (i.e. object detection), direction of motion (i.e. motion detection) and discrimination of oriented gratings (i.e. visual acuity). Two types of real-world orientation and mobility (O&M) tests were also performed: one test asked patients to locate and touch a door, and the second test asked patients to follow a white line on the floor. The ability to find a door and follow a line have real-world meaning with respect to mobility, ambulation and safety.

Earlier results from this trial were used to gain FDA approval of the Argus II in addition to CE Mark in Europe. The Argus II is the first and only retinal implant to have both approvals, and is the only system to have demonstrated long-term reliability and benefit. Today, nearly 200 patients have been treated with the Argus II.

Positive results of this long-term clinical study follow news about the Argus II’s long-term cost effectiveness published in 2014. Researchers evaluated the costs of using the Argus II over 25 years beginning at age 46 (the estimated average age that patients with RP are diagnosed as legally blind) and found that the incremental cost per ratios for the Argus II were about 16,000 US Dollars/quality-adjusted life year – well below payers’ cost utility thresholds and costs of “care as usual.”[2],[3]

Current research efforts by Second Sight include a feasibility study of the Argus II for individuals with dry age-related macular degeneration; hardware and software upgrades for existing and future Argus II patients; and the development of an advanced visual prosthesis, the Orion™ I Visual Cortical Prosthesis, aimed at patients with nearly all other forms of blindness. (Original Source)

Shares of Second Sight Medical Products opened today at $4.19, down $0.05 or 1.21%. EYES has a 1-year high of $14.95 and a 1-year low of $3.17. The stock’s 50-day moving average is $3.85 and its 200-day moving average is $4.47.

On the ratings front, Rodman & Renshaw analyst Amit Dayal reiterated a Buy rating on EYES, with a price target of $16, in a report issued on July 22. The current price target represents a potential upside of 286.5% from where the stock is currently trading. According to, Dayal has a yearly average return of -17.7%, a 30.0% success rate, and is ranked #3874 out of 4081 analysts.

Second Sight Medical Products, Inc. creates a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations such as Retinitis Pigmentosa. It manufactures and market implantable visual prosthetics to enable blind individuals to overcome disability and achieve greater independence.